A clinical longitudinal study of multiple sclerosis in Cantabria, Spain

Neurologia

Volumn 18, Issue 10, 2003, Pages 723-730

  Moris, Germán ^a,b   Berciano, J ^a   Miro J ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Hospital Alvarez Buylla   (Austria)

Author keywords

Azathioprine; Beta interferon; Clinical course; EDSS; Multiple sclerosis; Outcome

Indexed keywords

AZATHIOPRINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA INTERFERON; CARBAMAZEPINE; COPOLYMER; METHYLPREDNISOLONE; OXYBUTYNIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PYRAMIDAL SIGN; RATING SCALE; SENSORY DYSFUNCTION; SPAIN;

ADULT; CATCHMENT AREA (HEALTH); DISABILITY EVALUATION; HUMANS; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; SPAIN;

EID: 0346787764     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 1980;103:281-300.
2. Antón Aranda E, Martinez-Lage JM, Maravi Petri E, Gallego Cullere J, de Castro P, Villanueva Eusa JA. Epidemiology and clinical evolutionary aspects of multiple sclerosis in Navarra. Neurologia 1991;6:160-9.
3. Uría DF. Historia natural y factores pronósticos de la esclerosis múltiple. Rev Esp Neurol 1992;7:135-62.
4. García-Gallego A, Morera-Guitart J. Prevalence and characteristics of multiple sclerosis in the health district of the Marina Alta. Rev Neurol 2002;34:732-7.
5. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, and the Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology 1998;51:765-72.
6. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
7. Thompson AJ, Hutchinson M, Brazil J, Feighery C, Martin EA. A clinical and laboratory study of benign multiple sclerosis. Q J Med 1986;58:69-80.
8. Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand 1982;6:355-62.
9. Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976-1980. Acta Neurol Scand 1982;65:248-66.
10. Phadke JG. Clinical aspects of multiple sclerosis in North East Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-628.
11. Riise T, Gronning M, Fernández O, Lauer K, Midgard R, Mindderhoud JM, et al. Early prognostic factors for disability for multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992;85:212-8.
12. Rodriguez M, Siva A, Ward J, Stolp-Smith K, O'Brien P, Kurland L. Impairment, disability and handicap in multiple sclerosis: A population-based study in Olmsted Country, Minnesota. Neurology 1994;44:28-33.
13. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with 25 years follow-up. Brain 1993;116:117-34.
14. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 1989;112:133-46.
15. Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis. A 3-year follow-up study. Arch Neurol 1996;53:353-8.
16. Palace J, Rothwell P. New treatments and azathioprine in multiple sclerosis. Lancet 1997;350:261.
17. Cavazzuti M, Merelli E, Tassone G, Mavilla L. Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur Neurol 1997;38:284-90.
18. Lhermitte F, Marteau R, Roullet E. No so benign long-term immunosupresion in multiple sclerosis? Lancet 1984;1;276-7.
19. Confavreux C, Saddier P, Grimaud J, Moreau Th, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis. Neurology 1996;46:1607-12.
20. Mirȯ J, Aguayo F, Garrido JC, Alvarez C, Polo JM, Pascual J, et al. Intrathecal immunoglobulin synthesis in multiple sclerosis. Effect of corticosteroids and azathioprine. Eur Neurol 1992;32:349-53.
21. Poser C, Paty D, Scheinberg L, McDonald WI, Davis FA, Ebers JC, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983;13:227-31.
22. Lublin FD, Reingold SC, for the National Sclerosis Society (USA) Advisory Committee on clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Result of an international survey. Neurology 1996;46:907-11.
23. Kurtzke JF. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
24. Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148-52.
25. Paty DW, Oger JJF, Kastrukoff LH, Hashimoto SA, Hooge JP, Elsen AA, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988;38:180-5.
26. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-52.
27. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, et al. Primary progressive multiple sclerosis. Brain 1997;120:1085-96.
28. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-9.
29. Andersson PB, Goodkin DE. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998;160:16-25.
30. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-78.
31. Rudick RA, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med 1997;337:1604-11.
32. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.